[Treatment of ITP]

Area of Science:

• Hematology
• Immunology
• Gastroenterology

Background:

• Idiopathic thrombocytopenic purpura (ITP) management varies based on Helicobacter pylori status.
• Current guidelines in Japan prioritize Helicobacter eradication for positive ITP patients.

Purpose of the Study:

• To outline current treatment strategies for idiopathic thrombocytopenic purpura (ITP).
• To review first- and second-line treatment options for ITP, including corticosteroids, TPO-RAs, rituximab, and splenectomy.
• To highlight the challenges in managing refractory ITP and the need for novel therapies.

Main Methods:

• Review of current therapeutic approaches for ITP.
• Comparison of efficacy, duration, and complications of second-line treatments (TPO-RAs, rituximab, splenectomy).

Main Results:

• Helicobacter eradication is first-line for H. pylori-positive ITP.
• Corticosteroids are first-line for H. pylori-negative or eradicated ITP with low platelets or bleeding.
• Second-line options (TPO-RAs, rituximab, splenectomy) have distinct profiles: TPO-RAs (high efficacy, long-term need), rituximab (short course, low durable response), splenectomy (high durable response, long-term complications).

Conclusions:

• Treatment choice for refractory ITP requires balancing benefits and risks of second-line therapies.
• Established treatments for refractory ITP after second-line failure are lacking.
• Novel drug development is ongoing, with expectations for future treatment strategy establishment.